INGR1D Study: early detection of type 1 diabetes risk

INGR1D Study: early detection of type 1 diabetes risk

Recent studies showed that in children with an increased genetic risk of type 1 diabetes, the harmful immune system response leading to this disease often begins in the first months of life. Therefore, GPPAD scientists and physicians aim to prevent the development of this immune reaction as early as possible. To achieve this, it is necessary to first identify children at increased genetic risk for type 1 diabetes by investigating certain genes associated with this disease. Studies identifying these children as newborns are available across Europe under different names as part of GPPAD. In the UK, parents in Oxfordshire, Buckinghamshire and Berkshire can have their children tested free of charge together with the standard newborn screening as part of the INGR1D study.


The INGR1D Study Team
Nuffield Department of Women’s and Reproductive Health, University of Oxford
The Women’s Centre, John Radcliffe Hospital
Phone: 01865 572258

Phone: 01865 572258

>> DOWNLOAD study leaflet
>> DOWNLOAD poster

Secured By miniOrange